1819 results about "Fibrosis" patented technology

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib monotherapy as the main component to a subject in need thereof, as well as diagnostic criteria and markers establishing the progress of therapy.

Disclosed herein are apparatuses, systems, kits, and methods for treating skin, such as skin tightening or for treating diseases, disorders, and conditions that would benefit from tissue area or volume reduction, skin restoration, skin tightening, skin lifting, and / or skin repositioning and / or for generally improving skin function or appearance (e.g., the removal of unwanted skin features or irregularities such as sebaceous glands, sweat glands, hair follicles, necrosis, and fibrosis). Such apparatuses, systems, kits, and methods comprise an apparatus having a handheld main body and a detachably attachable tip comprising one or more needles.

The invention discloses a stem cell preparation for improving function degeneration of prostatitis and a preparation method and application thereof, and relates to the technical field of stem cells, the stem cell preparation is prepared from mesenchymal stem cells UC-MSCs and ADSCs according to the cell concentration ratio of 1: 2, hyaluronic acid hydrogel is used as a delivery carrier, and the stem cell preparation is prepared from the mesenchymal stem cells UC-MSCs and ADSCs according to the cell concentration ratio of 1: 2. And two key auxiliary components of juniperus formosana extract and mulberry extract are introduced. Wherein the optimal combination of the UC-MSCs and the ADSCs significantly enhances the anti-inflammatory ability and the tissue regeneration effect; the hyaluronic acid hydrogel carrier system effectively improves the targeting delivery efficiency of the stem cells and prolongs the action time; the two natural active components of the juniperus formosana extract and the mulberry extract synergistically improve the local microenvironment of prostate and inhibit inflammatory response and fibrosis process. The stem cell preparation developed through a multi-component synergistic effect mechanism has the characteristics of high targeting property, lasting treatment effect, high safety and the like, and a new strategy is provided for clinical treatment of prostatitis.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The present invention discloses a culture medium, a fermentation method and an application of Streptomyces for producing pieridian glycosides. Through this fermentation method, the Streptomyces can produce abundant pieridian glycosides, and its effective part contains more than 8 types of pieridian glycosides at the same time, and the content of the four types of pieridian glycosides, namely compound 4, compound 5, compound 6 and compound 8, is greater than 5%. The extract obtained by the strain through this fermentation method and its effective part can be used to prepare drug lead compounds for treating renal cancer, organ fibrosis, acute kidney injury and chronic kidney disease, and can provide drug source guarantee for China's marine drug research and development.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and / or regenerative responses. The disclosure also provides methods for treating or ameliorating disease, disorders and conditions associated with gp130 activity, particularly those associated with inflammatory and degenerative disorders, or combination thereof.

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.

The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a BET (bromodomain and extra-terminal protein) inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more JAK inhibitors. Also provided are medicaments for use in treating cancer.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.

The invention relates to a construction method of a thyroid-related eye disease animal model, and belongs to the technical field of biology. The invention provides a thyroid-associated ophthalmopathy animal model construction method, which comprises: (1) separating and purifying in vitro peripheral blood collected from a thyroid-associated ophthalmopathy patient to obtain an exosome; and (2) injecting the exosome into a to-be-modeled animal to prepare the thyroid-associated ophthalmopathy animal model. According to the invention, exosomes are extracted from in-vitro peripheral blood of patients with thyroid-associated ophthalmopathy and are injected into animals, so that the thyroid-associated ophthalmopathy animal model with a plurality of pathological characteristics such as orbital tissue inflammatory response, fibrosis, orbital lesion, thyroid dysfunction and the like is successfully constructed; the method can be widely applied to pathological mechanism research of thyroid-related eye diseases and screening and evaluation of thyroid-related eye disease treatment drugs.

The invention discloses a preparation method of a stem cell exosome chitosan compound covered stent. The stem cell exosome chitosan compound comprises a stem cell exosome and a chitosan compound. In the stem cell exosome and chitosan compound, the mass percent of chitosan is 3%-10%, and the number of the stem cell exosomes is 109-1011. Compared with a traditional covered stent, the covered material provided by the invention can resist inflammation, inhibit bacteria, protect vascular endothelial cells covered by the stent, promote tissue repair, prevent tissue adhesion, prevent fibrosis and inhibit exclusion reaction and autoimmunity.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

A method for assessing nonalcoholic steatohepatitis (NASH) cirrhosis in a liver biopsy sample includes extracting, from the liver biopsy sample, image data indicative of one or more histopathological features, wherein the one or more histopathological features comprise septa and / or nodules and / or fibrosis, and analysing the extracted image data, using a machine learning model trained to assess the one or more histopathological features, to determine a degree of NASH cirrhosis. Training the machine learning model includes providing a plurality of training samples and a plurality of validation samples, each sample comprising a graded liver biopsy sample; quantifying parameters of the one or more histopathological features from image data of each of the training samples; selecting a subset of quantified parameters of the one or more histopathological features; constructing a model for assessing the one or more histopathological features from the subset of quantified parameters; and validating the constructed model using the validation samples.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.

The invention belongs to the technical field of biomedical materials and regenerative medicine, and relates to collagen-based injectable fiber hydrogel as well as a preparation method and application thereof. According to the injectable fiber hydrogel, methacrylated collagen and dithiothreitol are subjected to a thiol-ene click reaction rapidly under the action of a photoinitiator through illumination, a primary cross-linked network is formed, and the injection and in-situ gel forming requirements are met; then under the conditions that the pH is 6.5-8.0 and the temperature is 30-39 DEG C, collagen molecules are self-assembled into a nanofiber structure, and a bionic network similar to a natural extracellular matrix is obtained. The hydrogel disclosed by the invention has the advantages of rapid gelation, structural biomimetic property and biological activity; residual sulfydryl endows the hydrogel with active oxygen scavenging capacity, so that oxidative stress can be relieved, and immune response can be regulated; the fibrotic structure promotes cell adhesion, migration and tissue regeneration.

Systems and methods for capturing and processing image data captured by an optical microscope, such as an Open Top Light Sheet (OTLS) microscope are disclosed. Image data can be processed by techniques including flat fielding, image depth correction, and edge correction, and pixel classification and image segmentation techniques can be applied to more accurately identify lipid droplets and fibrous structures for assessment of, for example, steatosis and fibrosis in human liver biopsy tissue samples. Systems and methods are also related to capturing low resolution images of a sample, identifying regions of interest, and then capturing high resolution image of the regions of interest to reduce memory used for storage, increase computation speed, and reduce computational power.

The instant invention relates to a semi-solid topical composition containing Pirfenidone and an antimicrobial / antiseptic agent such as Modified Diallyl Disulfide Oxide (M-DDO) and its preparation process, offering advantages compared to other pharmaceutical forms of topical administration known in the state of the art, useful as antifibrotic, anti-inflammatory and antiseptic agent in the prevention, treatment and reversion of acne and post acne lesions. Said compositions is also useful for reducing skin redness, detaining the formation of new acne outbreaks, reversing already existing outbreaks and regenerating skin damage caused by acne.